Agennix Receives FDA Nod for Phase III Lung Cancer Trial
Posted on: Thursday, 17 January 2008, 09:01 CST
Agennix has reported that the FDA has approved the design of a single, pivotal, Phase III trial evaluating its lead molecule, talactoferrin alfa, in combination with chemotherapy as first-line treatment in patients with non-small cell lung cancer under the special protocol assessment process.
The Phase III, multinational, randomized, double-blind, placebo-controlled study will enroll 1,100 previously untreated patients with Stage IIIB or IV non-small cell lung cancer (NSCLC). The patients will be randomly assigned to receive up to six cycles of standard chemotherapy (carboplatin and paclitaxel) plus either oral talactoferrin or placebo. Following six cycles of chemotherapy, or discontinuation prior to six cycles for reasons other than progression, patients will receive talactoferrin or placebo as maintenance therapy until disease progression. Progression-free survival and overall survival will be the primary endpoints for accelerated approval and regular approval, respectively. Secondary endpoints include adverse event reductions, confirmed response rate, duration of response and safety.
Agennix also received scientific advice from the European Medicines Agency (EMEA) indicating that this single trial will also support a marketing authorization application in the EU.
Waun Ki Hong, member of Scientific Advisory Board at Agennix, said: "Talactoferrin has the potential to be an important advance in the treatment of NSCLC. I look forward to confirmation of the Phase II results in the Phase III trials."
Source: Datamonitor
Related Articles
- Insomnia Prevalent Among Cancer Patients Who Receive Chemotherapy
- New Test to Predict How Breast Cancer Patients Respond to Chemotherapy
- ThromboGenics Announces Promising Six Month Follow-Up Results From Its Phase IIb Trial of Microplasmin (MIVI III) for Treatment of Visual Disorders
- PAION Announces Phase I Study With Sedative/Anaesthetic CNS 7056 Progressed to Midazolam Comparison; Today Company Presentation at UBS Global Life Sciences Conference
- Data From Pivotal Phase III Studies of Gilead's Letairis(R) (Ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients With WHO Functional Class II or III Symptoms Published in Circulation
- Pro-Pharmaceuticals Phase II Trial Shows DAVANAT(R) Improves Median Progression Free Survival With Fewer Side Effects As Compared to Recent Similar Studies
- Results of 340 Patient Phase III Study Using BSD Medical's Cancer Therapy Systems to Be Announced at ASCO Annual Meeting
- Axonyx Completes First Phase I Trial With Posiphen for Alzheimer's Disease Progression
- Cobalis Corp. PreHistin(TM) Significantly Reduces Allergy Symptoms in 714 Patient Phase 3 Clinical Trial
- New Two-Year Data Show That Most Rheumatoid Arthritis Patients Treated With ENBREL Plus Methotrexate Had No Progression of Joint Damage
 |
 |
User Comments (0)
RSS Feeds